Sales of IZERVAY TM (Preliminary Figures)

TOKYO, July 10, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the sales in the U.S. of the IZERVAY TM (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in the first quarter of FY2025 (April 1, 2025 – June 30, 2025) was ¥15.9 billion/ $110 million (preliminary figures). This information has been disclosed in conjunction with today's meeting for the investment community. Astellas’ financial results for the first quarter of FY2025, including IZERVAY’s sales, will be disclosed and explained at Astellas’ Q1 earnings call scheduled on July 30, 2025. About Astellas Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com . Cautionary Notes In this press release, statements made concerning current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs considering the information currently available to it and involve known and unknown risks and uncertainties. Several factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) included in this press release is not intended to constitute an advertisement or medical advice. Sales of IZERVAY TM (Preliminary Figures)

The release as fetched from its publisher. astellas.com ↗